Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 4/20 | 0.75 |
| ▸ | GRIA4 | P48058 | 13/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622512 | 0.89 | GRIA1 (0.62) | GRIA1GRIA4NPY5R | |
| SCHEMBL8366386 | 0.86 | GRIA1 (0.65) | GRIA1GRIA4CA1 | |
| SCHEMBL7109326 | 0.86 | GRIA1 (1.00) | GRIA1GRIA4CA1NPY5R | |
| SCHEMBL7039391 | 0.86 | GRIA1 (1.00) | GRIA1GRIA4CA1NPY5R | |
| SCHEMBL7042049 | 0.86 | GRIA1 (1.00) | GRIA1GRIA4CA1NPY5R | |
| SCHEMBL147252 | 0.86 | GRIA1 (0.65) | GRIA1GRIA4CA1GRIA2GRIA3 | |
| SCHEMBL25435565 | 0.84 | GRIA1 (0.62) | GRIA1GRIA4GRIA2GRIA3NPY5R | |
| SCHEMBL18198023 | 0.84 | GRIA1 (0.62) | GRIA1GRIA4 | |
| SCHEMBL147253 | 0.84 | GRIA1 (0.62) | GRIA1GRIA4NPY5R | |
| SCHEMBL5107732 | 0.84 | GRIA1 (0.62) | GRIA1GRIA4GRIA2GRIA3NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319396-B2 | Star-shaped and triblock polymers with enhanced crosslinkability | BASF SE (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20200317847-A1 | STAR-SHAPED AND TRIBLOCK POLYMERS WITH ENHANCED CROSSLINKABILITY | CLAP CO., LTD. (KR) | 2020-10-08 | — | — | US | disclosed |
| US-8440417-B2 | Method for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-20090286261-A1 | METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | CAYMAN CHEMICAL COMPANY (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286261-A1 | METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, HPGD, GMDS | GRIA1 2532/4885GRIA4 3427/4885CA1 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.